![]() 10x Genomics Profileġ0x Genomics, Inc, a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in North America, Europe, the Middle East, Africa, China, and the Asia Pacific. 10.65% of the stock is owned by company insiders. Insiders have sold a total of 53,655 shares of company stock valued at $2,881,404 over the last 90 days. The disclosure for this sale can be found here. Following the completion of the transaction, the director now owns 333,736 shares of the company’s stock, valued at $18,318,769.04. The shares were sold at an average price of $54.89, for a total value of $548,900.00. Stuelpnagel sold 10,000 shares of the firm’s stock in a transaction that occurred on Monday, June 5th. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Following the completion of the transaction, the chief executive officer now directly owns 895,792 shares in the company, valued at $47,790,503.20. The stock was sold at an average price of $53.35, for a total transaction of $106,700.00. In related news, CEO Serge Saxonov sold 2,000 shares of the stock in a transaction dated Monday, May 15th. will post -1.42 EPS for the current year. On average, equities research analysts forecast that 10x Genomics, Inc. During the same period in the prior year, the business earned ($0.38) EPS. The company’s revenue for the quarter was up 17.3% compared to the same quarter last year. 10x Genomics had a negative return on equity of 22.02% and a negative net margin of 32.51%. The business had revenue of $134.29 million for the quarter, compared to analyst estimates of $128.87 million. The company reported ($0.44) EPS for the quarter, missing analysts’ consensus estimates of ($0.38) by ($0.06). has a one year low of $23.81 and a one year high of $60.00.ġ0x Genomics ( NASDAQ:TXG – Get Free Report) last released its quarterly earnings results on Wednesday, May 3rd. The stock’s 50-day moving average is $55.25 and its 200-day moving average is $50.75. Institutional investors and hedge funds own 76.71% of the company’s stock. now owns 686,270 shares of the company’s stock valued at $52,204,000 after acquiring an additional 485,997 shares during the period. ![]() lifted its stake in shares of 10x Genomics by 242.7% during the first quarter. Man Group plc acquired a new position in shares of 10x Genomics during the fourth quarter valued at $19,787,000. Norges Bank acquired a new position in shares of 10x Genomics during the fourth quarter valued at $32,616,000. ![]() ![]() Millennium Management LLC now owns 1,213,394 shares of the company’s stock valued at $44,216,000 after acquiring an additional 999,487 shares during the period. Millennium Management LLC lifted its stake in shares of 10x Genomics by 467.3% during the fourth quarter. now owns 9,156,992 shares of the company’s stock valued at $696,572,000 after acquiring an additional 1,138,358 shares during the period. lifted its stake in shares of 10x Genomics by 14.2% during the first quarter. Several other institutional investors have also bought and sold shares of TXG. State of New Jersey Common Pension Fund D’s holdings in 10x Genomics were worth $2,757,000 at the end of the most recent quarter. The institutional investor owned 49,416 shares of the company’s stock after selling 13,805 shares during the quarter. ( NASDAQ:TXG – Free Report) by 21.8% during the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). State of New Jersey Common Pension Fund D decreased its stake in 10x Genomics, Inc. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |